Tetrous, Inc.

News

TETROUS ANNOUNCES FIRST ENFIX RC™ SURGICAL CASES OUTSIDE THE UNITED STATES

July 13, 2023

Tetrous Inc., a leading regenerative medicine company today announced that it has completed the first surgical cases in Australia using EnFix RC, a procedure-specific implant for rotator cuff repair that is specifically designed to address Enthesis Failure Syndrome. The procedures were performed successfully by Dr. Kenneth Cutbush, Dr. Ivan Popoff and Dr. Doron Sher.

Read More »

FIRST SURGICAL PROCEDURES IN THE WORLD USING TETROUS ENFIX RC™ FIBER IMPLANT TO ENHANCE ROTATOR CUFF REPAIR PERFORMED AT RUSH OAK BROOK SURGERY CENTER

July 11, 2023

Tetrous Inc., a leading regenerative medicine company today announced that it has completed the first four surgical cases using EnFix RC, a procedure-specific implant for rotator cuff repair that is specifically designed to address Enthesis Failure Syndrome. Dr. Nikhil Verma, MD. Professor and Director, Division of Sports Medicine, Fellowship Director, Department of Orthopedics, Rush University Medical Center, Team Physician Chicago White Sox and Chicago Bulls, who performed the first four surgeries with the EnFix RC said: “I was thrilled to be the first surgeon to deploy the EnFix RC. I used one EnFix RC in each case to augment the medial suture anchor fixation. Initially I was impressed with the concept of flipping the script compared to most of the products today for surgical augmentation. I also was very pleased with how the implant and instrument design was optimized, simplifying the delivery of the product into the interface between the tendon and the bone. The procedure is minimally disruptive to the way rotator cuff surgeries are typically performed. I plan to use the EnFix RC routinely moving forward.”

Read More »

Events

Tetrous, Inc.

© Tetrous, Inc. All rights reserved.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.